文献速递胃肠外科围术期管理与 ERAS

局部晚期直肠癌新辅助放疗不完整与生存的关联

Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer.
PubMed 文献 · JAMA Surg · 2017-01-01

不完整放疗占5.0%,其中位剂量34.2 Gy;完整放疗者5年总生存率73.2% vs 63.0%,校正后长期死亡风险显著降低(aHR 0.70),但切缘阳性、永久造口、30天再入院和90天死亡率无显著差异。

要点

  • 完整新辅助放疗(45.0-50.4 Gy)与局部晚期直肠癌长期生存改善独立相关。
  • 不完整放疗占5.0%,中位剂量34.2 Gy,女性及跨院放疗是独立预测因素。
  • 完整与不完整放疗在切缘阳性、永久造口、再入院和90天死亡率上无显著差异。

核心结论

  • 达到45.0-50.4 Gy目标放疗剂量与局部晚期直肠癌生存获益相关。
  • 协调多模式肿瘤治疗的各环节可能提高新辅助治疗完成概率。

研究设计与样本

  • 所有患者接受新辅助放化疗后行手术切除,比较完整放疗(45.0-50.4 Gy)与不完整放疗(<45.0 Gy)。
  • 采用多变量回归方法比较切缘阳性、永久造口率、30天再入院、90天死亡率和总生存。

主要发现

  • 女性(aOR 0.69;95%CI 0.59-0.81;P<.001)和在非手术医院接受放疗(OR 0.72;95%CI 0.62-0.85;P<.001)是未完成放疗的独立预测因素。
  • 私人保险状态预测完成放疗(OR 1.60;95%CI 1.16-2.21;P=.004)。
  • 5年随访时完整放疗组总生存改善(3086例,估计生存概率73.2% vs 133例,63.0%;P<.001)。
  • 校正人口学、临床和肿瘤特征后,完整vs不完整放疗的切缘阳性(OR 0.99;95%CI 0.72-1.35;P=.92)、永久造口率(OR 0.96;95%CI 0.70-1.32;P=.81)、30天再入院(OR 0.92;95%CI 0.67-1.27;P=.62)和90天死亡率(OR 0.72;95%CI 0.33-1.54;P=.41)无显著差异。

临床怎么用

  • 对局部晚期直肠癌患者,应努力完成45.0-50.4 Gy的新辅助放疗剂量以争取生存获益。
  • 关注女性及跨院放疗患者,识别不完整放疗高风险人群并优化治疗衔接。
  • 短期围手术期结局(切缘、造口、再入院、90天死亡)不因放疗是否完整而显著改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Failing to complete chemotherapy adversely affects survival in patients with colorectal cancer. However, the effect of incomplete delivery of neoadjuvant radiotherapy is unclear. OBJECTIVE: To determine whether incomplete radiotherapy delivery is associated with worse clinical outcomes and survival. DESIGN, SETTING, AND PARTICIPANTS: Data on 17 600 patients with stage II to III rectal adenocarcinoma from the 2006-2012 National Cancer Database who received neoadjuvant chemoradiotherapy followed by surgical resection were included. Multivariable regression methods were used to compare resection margin positivity, permanent colostomy rate, 30-day readmission, 90-day mortality, and overall survival between patients who received complete (45.0-50.4 Gy) and incomplete (<45.0 Gy) doses of radiation as preoperative therapy. MAIN OUTCOMES AND MEASURES: The primary outcome measure was overall survival; short-term perioperative and oncologic outcomes encompassing margin positivity, permanent ostomy rate, postoperative readmission, and postoperative mortality were also assessed. RESULTS: Among 17 600 patients included, 10 862 were men, with an overall median age of 59 years (range, 51-68 years). Of these, 874 patients (5.0%) received incomplete doses of neoadjuvant radiation. The median radiation dose received among those who did not achieve complete dosing was 34.2 Gy (interquartile range, 19.8-40.0 Gy). Female sex (adjusted odds ratio [OR] 0.69; 95% CI, 0.59-0.81; P < .001) and receiving radiotherapy at a different hospital than the one where surgery was performed (OR, 0.72; 95% CI, 0.62-0.85; P < .001) were independent predictors of failing to achieve complete dosing; private insurance status was predictive of completing radiotherapy (OR, 1.60; 95% CI, 1.16-2.21; P = .004). At 5-year follow-up, overall survival was improved among patients who received a complete course of radiotherapy (3086 [estimated survival probability, 73.2%] vs 133 [63.0%]; P < .001). After adjustment for demographic, clinical, and tumor characteristics, patients receiving a complete vs incomplete radiation dose had a similar resection margin positivity (OR, 0.99; 95% CI, 0.72-1.35; P = .92), permanent colostomy rate (OR, 0.96; 95% CI, 0.70-1.32; P = .81), 30-day readmission rate (OR, 0.92; 95% CI, 0.67-1.27; P = .62), and 90-day mortality (OR, 0.72; 95% CI, 0.33-1.54; P = .41). However, a complete radiation dose had a significantly lower risk of long-term mortality (adjusted hazard ratio, 0.70; 95% CI, 0.59-0.84; P < .001). CONCLUSIONS AND RELEVANCE: Achieving a target radiation dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients with locally advanced rectal cancer. Aligning all aspects of multimodal oncology care may increase the probability of completing neoadjuvant therapy.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Freischlag K, Sun Z, Adam MA, et al. Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. JAMA Surg. 2017. PMID: 28273303. doi:10.1001/jamasurg.2017.0010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。